Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Three psoriasis experts join the group of respected IPC Councilors

IPC is pleased to introduce and welcome our three newest councilors for 2022: Alexander Egeberg, Kilian Eyerich, and Julia-Tatjana Maul. Bringing diverse and broad experience in the field of psoriasis, they join an esteemed group of experts working to improve care for psoriasis patients around the world. IPC Councilors serve in an advisory capacity and lend their global expertise on psoriasis research, treatment, and education to support all IPC programs, events, and initiatives. They are selected based on their overall reputation in the dermatology community, experience in clinical or investigative research in psoriasis, level of clinical expertise in patient care, and demonstrated professional interest in psoriasis. Learn more about IPC Councilors and read their full biographies.

Meet our newest councilors


Alexander Egeberg, MD, PhD, DMSc
Bispebjerg Hospital
Copenhagen, Denmark

Dr. Egeberg is an associate professor and senior consultant at the Department of Dermatology at Bispebjerg Hospital, Copenhagen, Denmark, where he serves as the head of one of the largest psoriasis clinics in Northern Europe with more than 1,500 patients on biologic therapy, as well as the head of the psoriasis clinical trial unit. As a board-certified dermatologist, he earned his MD from the University of Southern Denmark and his PhD and doctoral degree of medical science (DMSc) from the University of Copenhagen. Dr. Egeberg also holds a post-graduate degree in Economics from Copenhagen Business School.
Having authored more than 250 international scientific publications, as well as several textbook chapters, he is an expert in inflammatory skin diseases with broad experience in epidemiology, real-world evidence, translational medicine, and clinical trials. From his involvement in global steering committees and as investigator in numerous global clinical trial programs, he has extensive knowledge about drug development, has served on global Data Safety Monitoring Boards, and has been acting advisor for the European Medicines Agency.

Last Updated: Jan 18, 2022

Kilian Eyerich, MD, PhD
Karolinska Institutet
Stockholm, Sweden

Kilian Eyerich is chair and professor at the Department of Dermatology and Venerology of the University of Freiburg, Germany, as well as guest professor at the Karolinska Institute in Stockholm, Sweden. He was previously Heisenberg professor for Dermato-Immunology at the Technical University Munich, Germany. His scientific interest is the interaction of adaptive immune cells and resident epithelial cells in inflammatory skin diseases. His vision is to revise the disease ontology of inflammatory and autoimmune skin diseases based on a clinically meaningful molecular basis. Kilian Eyerich is PI in numerous translational research projects and clinical trials in the field. He has published more than 150 scientific articles in peer-reviewed journals such as the New England Journal of Medicine as well as journals of the Nature and Science group. His work received numerous awards such as two European Research Council grants and a Heisenberg professorship. He serves as a board member and advisor of numerous academic and private scientific organizations such as being deputy editor of the Journal of Investigative Dermatology.

Last Updated: Feb 14, 2022

Julia-Tatjana Maul, MD
University Hospital of Zurich
Z├╝rich, Switzerland
2020 Fellow

PD Dr. Julia-Tatjana Maul is a senior physician in the Department of Dermatology at the University Hospital of Zürich, Switzerland. She was elected as the head of the clinical trials team and is the leading physician of the psoriasis and hidradenitis suppurativa clinic. PD Dr. Maul is the principal investigator (PI) of several clinical trials such as the national PI of the Swiss psoriasis registry SDNTT (Swiss Dermatology Network for Targeted Therapy) and the International pustular psoriasis registry IRASPEN.
PD Dr. Maul graduated from the Medical School at the University of Tübingen, Germany in 2011. Between 2011 and 2013 she did part of her residency in the Oncology Department at the University Hospital of Zürich, Switzerland prior to transitioning to the Dermatology Department.
PD Dr. Maul's main research activities are focused on psoriasis by investigating the drug survival of biologics and conventional systemics, gender differences in treatment response and access to treatment.
She holds a leadership position at the Global Psoriasis Atlas (GPA) as their `Global Medical Coordinator`. Furthermore, she is involved in the European Psoriasis Guidelines and co-authored the chapters cancer, pregnancy, and diabetes.
Due to her strong interest in psoriasis-associated gender medicine she is a part of the commission "Sex and Gender in Medicine" of the Medical Faculty of the University of Zurich, American Women´s Society of Dermatology and Co-Chair of the Pregnancy Task Force of the European Association of Dermatology and Venereology.

Last Updated: Feb 01, 2022


Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now


on SARS-CoV-2 Vaccines and Psoriasis

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.